# US 10,441,575 B2 · Drug compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,441,575 B2
- Document ID: US10441575B2
- Status: Granted
- Kind: B2
- Application number: 15/914,804
- Filed: 2018-03-07
- Published: 2018-07-12
- Granted: 2019-10-15
- Earliest claimed: 2016-08-11
- Assignees: Adamis Pharmaceuticals Corporation
- Applicants: Adamis Pharmaceuticals Corporation
- Inventors: David Clayton Sutherland; James Kyle Zorn; Dennis J. Carlo
- Web page: https://patentgrep.com/patent/US10441575B2

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 9/10: Dispersions; Emulsions
- A61K 9/145: {with organic compounds}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C01D 5/14: Preparation of sulfites (C01D5/04 takes precedence)
- C01D 7/10: Preparation of bicarbonates from carbonates (ammonia soda process C01D7/18)
- C08B 3/06: Cellulose acetate {, e.g. mono-acetate, di-acetate or tri-acetate}
- C08L 1/286: {substituted with acid radicals, e.g. carboxymethyl cellulose [CMC] (C08L1/282 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01D: COMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM (metal hydrides {monoborane, diborane or addition complexes thereof} C01B6/00; salts of oxyacids of halogens C01B11/00; peroxides, salts of peroxyacids C01B15/00; sulfides C01B17/22; thiosulfates, dithionites, polythionates C01B17/64; compounds containing selenium or tellurium C01B19/00; binary compounds of nitrogen with metals C01B21/06; azides C01B21/08; {compounds other than ammonia and cyanogen, containing nitrogen and other non-metals C01B21/082}; metal amides C01B21/092; nitrites C01B21/50; phosphides C01B21/50; {compounds of noble gases C01B23/0005}; phosphides C01B25/08; salts of oxyacids of phosphorus C01B25/16; carbides C01B32/90; compounds containing silicon C01B33/00; compounds containing boron C01B35/00; cyanides C01C3/08; salts of cyanic acid C01C3/14; salts of cyanamide C01C3/16; thiocyanates C01C3/20)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)

## Abstract

Described herein are pharmaceutical compositions including a proton pump inhibitor and an antiparasitic drug. In some embodiments, the compositions can be formulated as a non-solid for oral administration. The compositions can be used to treat gastrointestinal conditions. Methods of treatment using the compositions are also described.

## Claims

### Claim 1

A method of treating a gastrointestinal ulcer, the method comprising:
administering an oral paste including about 22% w/v omeprazole, about 30% w/v fenbendazole, and a wetting agent formulated in a melted polyethylene glycol base agent to a mammal having the gastrointestinal ulcer, and
treating the gastrointestinal ulcer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the administration is performed using an oral syringe.

### Claim 3 (depends on 1)

The method of claim 1, wherein the mammal is a human, a horse, or a camel.

### Claim 4 (depends on 1)

The method of claim 1, wherein the gastrointestinal ulcer is greater than Grade 1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treating is clinical healing resulting in an ulcer score less than 1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the treating is clinical healing resulting in an ulcer score of 0.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treating is in less than about 30 days.

### Claim 8 (depends on 1)

The method of claim 1, wherein the treating is in less than about 14 days.

### Claim 9 (depends on 1)

The method of claim 1, wherein the administering is once daily.

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering is twice daily.

### Claim 11 (depends on 1)

The method of claim 1, wherein the wetting agent is a polyethylene glycol.

### Claim 12 (depends on 1)

The method of claim 1, wherein the oral paste further includes sodium sulfite.

### Claim 13 (depends on 1)

The method of claim 1, wherein the oral paste further includes carboxymethyl cellulose.

### Claim 14 (depends on 1)

The method of claim 1, wherein the oral paste further includes sodium bicarbonate.

### Claim 15 (depends on 1)

The method of claim 1, wherein the oral paste further includes a flavoring agent.